Melinda Smith
Lexicon Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Diabetes Treatment and Management, Mitochondrial Function and Pathology, Pancreatic function and diabetes, ATP Synthase and ATPases Research
Most-Cited Works
- → An inhibitor of oxidative phosphorylation exploits cancer vulnerability(2018)924 cited
- → LX4211 Increases Serum Glucagon-Like Peptide 1 and Peptide YY Levels by Reducing Sodium/Glucose Cotransporter 1 (SGLT1)–Mediated Absorption of Intestinal Glucose(2013)181 cited
- → Improved glycemic control in mice lacking Sglt1 and Sglt2(2012)157 cited
- → Anxiety disorders in adolescence: Characteristics, prevalence, and comorbidities(1994)95 cited
- → Panic in otolaryngology patients presenting with dizziness or hearing loss(1994)94 cited
- → Identifying anxiety disorders in adolescents hospitalized for alcohol abuse or dependence(1995)81 cited
- → Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes(2013)77 cited
- → Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation(2019)67 cited
- → Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes(2017)64 cited
- → Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models(2014)51 cited